Healthcare Private Placement and M&A Transactions Review Week Ending Feb 2, 2025

Atalanta Therapeutics: The company raised $170 million of Series B venture funding in a deal led by Sanofi Ventures and EQT Life Sciences on January 28, 2025. Novartis, RiverVest Venture Partners, F-Prime Capital, Mirae Asset Capital, GHR Foundation, Pictet and Abrdn also participated in the round. The company is a developer of a ribonucleic acid (RNA) interference therapeutics platform intended to treat neurodegenerative diseases.

Helicore Biopharma: The company raised $65 million of Series A venture funding in a deal led by Versant Ventures and OrbiMed on January 28, 2025, putting the company’s pre-money valuation at $33 million. Longitude Capital, Wellington Management, Logos Capital, and other undisclosed investors also participated in the round. The company is a biopharmaceutical business developing innovative therapeutics to address obesity and related metabolic conditions.

Echo Neurotechnologies: The company raised an estimated $50 million of venture funding from Andreessen Horowitz and other undisclosed investors on January 31, 2025. The company is a developer of neuroscience products, including brain-computer interfaces to restore conversational communications, enabling patients with severe disabilities to interact with others.

SafelyYou: The company raised $43 million of Series C venture funding in a deal led by Touring Capital on January 28, 2025, putting the company’s pre-money valuation at $163 million. Qualcomm Ventures, Foundation Capital, Founders Fund, Cross Creek Advisors, Samsung NEXT Ventures and Omega Healthcare Investors also participated in the round. The company is an operator of an AI-based fall prevention technology development firm intended to detect critical care moments and on-the-ground events for patients with Alzheimer’s and other forms of dementia.

VideaHealth: The company raised $40 million in Series B venture funding in a deal led by Threshold Ventures on January 28, 2025, putting the company’s pre-money valuation at $360 million. Avenir Growth Capital, Zetta Venture Partners, Pillar VC, Spark Capital, BAM Ventures, and other undisclosed investors also participated in the round. The company is a developer of an artificial intelligence technology designed to detect pathologies in dental imaging automatically.

Imvax: The company raised $29 million of venture funding from undisclosed investors on January 29, 2025. The company is a developer of patient-specific vaccines and immunotherapy strategies designed for the treatment of malignant gliomas and other cancers with unmet medical needs.

EVOQ Nano: The company raised $18 million of venture funding from Tony Robbins and other undisclosed investors on January 30, 2025. The company is a developer of an antimicrobial nano particle technology designed to create precise novel product outcomes for numerous applications and for multiple drug administration pathways.

Nucleus: The company raised $14 million of Series A venture funding from Neo Medical (Surgical Devices), One Eight Capital and Giant Step Capital on January 30, 2025. Common Metal, Asylum Ventures, Rose Street Capital, Founders Fund, Seven Seven Six, Balaji Srinivasan, Achal Upadhyaya and Amanda Bradford also participated in the round. The company is an operator of a biotechnology research platform intended to offer next-generation consumer genetic testing and analysis.

Reprieve Cardiovascular: The company raised $9.5 million of venture funding in the form of convertible notes from undisclosed investors on January 27, 2025. The company is a developer of an acute decompensated heart failure (ADHF) medical device designed for heart fluid decongestion management.

Ethizo: The company raised $7.7 million of venture funding from undisclosed investors on January 27, 2025. The company is an operator of a digital health platform intended to offer disease management and telemedicine services.

Output Sports: The company raised EUR 4.5 million of venture funding in a deal led by Apex Capital (Portugal) on January 30, 2025. Atlantic Bridge Capital, Enterprise Ireland, UNI.FUND, Dopamine Sports Ventures, Jim Kelliher and Elkstone also participated in the round. The company is a developer of an off-field measuring tool for strength, power and movement analysis to optimize an athlete’s performance.

MH3D: The company raised $3.3 million of venture funding from undisclosed investors on January 30, 2025. The company is a developer of nuclear imaging technology designed for medical research.

Suki: The company raised an undisclosed amount of venture funding from Zoom Ventures on January 30, 2025. The company is a developer of a medical voice assistant intended to streamline the process of clinical documentation and reduce the administrative burden on healthcare providers.

Paragon 28 / Zimmer Biomet Holdings: The company reached a definitive agreement to be acquired by Zimmer Biomet Holdings for $1.2 billion on January 28, 2025. Paragon 28 Inc is a medical devices company that develops, distributes, and sells foot and ankle orthopedic implant medical devices.

Evergreen Theragnostics / Lantheus Medical Imaging: The company reached a definitive agreement to be acquired by Lantheus Medical Imaging for $250 million on January 28, 2025. The company is an operator of contract development and manufacturing platform intended to improve the available options for cancer patients through radiopharmaceuticals.

3motionAI / Benchmark Gensuite: The company was acquired by Benchmark Gensuite, via its financial sponsor Vista Equity Partners, through an LBO on January 30, 2025 for an undisclosed amount. The company is a developer of health technology platform intended to focus on preventing and resolving workplace injuries.

Advanced Orthopedics / Aspen Medical Products: The company was acquired by Aspen Medical Products, via its financial sponsors Cortec Group and Golub Capital, through an LBO on January 29, 2025 for an undisclosed amount. The company is a manufacturer and supplier of orthopedic braces and therapeutic products to support healing and recovery.

Appiture Biotechnologies / Schweitzer Engineering Laboratories: The company was acquired by Schweitzer Engineering Laboratories for an undisclosed amount on January 28, 2025. The company is an operator of a healthcare data analytics business intended to focus on biometric markers for behavioural conditions associated with autism spectrum disorder.

BetterHealthcare / HealthBus: The company was acquired by HealthBus for an undisclosed amount on January 29, 2025. The company is a developer of a physical therapy booking application platform.

Boston Medical Sciences / Eukaria: The company was acquired by Eukaria for an undisclosed amount on January 31, 2025. The company is a developer of a non-invasive colorectal cancer detection platform designed to improve patient outcomes.

Molecular Assemblies / Maravai LifeSciences: The company was acquired by Maravai LifeSciences for an undisclosed amount on January 28, 2025. The company is a developer of enzymatic deoxyribonucleic acid synthesis technology.

SeQure DX / MaxCyte: The company was acquired by MaxCyte for an undisclosed amount on January 30, 2025. The company is a developer of genomics diagnostic technologies designed for gene editor target profiling to advance discovery, clinical development, and diagnostic solutions.

ViSpot / Takara Bio: Takara Bio reached a definitive agreement to acquire the Company, a subsidiary of Sunstar, for an undisclosed amount on January 27, 2025. The company is a provider of virus testing services based in Kobe, Japan.